Abstract:Abstract Background Allergic diseases typically refer to a heterogeneous group of conditions primarily caused by the activation of mast cells or eosinophils, including atopic dermatitis (AD), allergic rhinitis (AR), and asthma. Asthma, AR, and AD collectively affect approximately one‐fifth of the global population, imposing a significant economic burden on society. Despite the availability of drugs to treat allergic diseases, they have been shown to be insufficient in controlling relapses and halting disease progression. Therefore, new drug targets are needed to prevent the onset of allergic diseases. Method We employed a Mendelian randomization approach to identify potential drug targets for the treatment of allergic diseases. Leveraging 1798 genetic instruments for 1537 plasma proteins from the latest reported Genome‐Wide Association Studies (GWAS), we analyzed the GWAS summary statistics of Ferreira MA et al. (nCase = 180,129, nControl = 180,709) using the Mendelian randomization method. Furthermore, we validated our findings in the GWAS data from the FinnGen and UK Biobank cohorts. Subsequently, we conducted sensitivity tests through reverse causal analysis, Bayesian colocalization analysis, and phenotype scanning. Additionally, we performed protein‐protein interaction analysis to determine the interaction between causal proteins. Finally, based on the potential protein targets, we conducted molecular docking to identify potential drugs for the treatment of allergic diseases. Results At Bonferroni significance ( p < 3.25 × 10 −5 ), the Mendelian randomization analysis revealed 11 significantly associated protein‐allergic disease pairs. Among these, the increased levels of TNFAIP3, ERBB3, TLR1, and IL1RL2 proteins were associated with a reduced risk of allergic diseases, with corresponding odds ratios of 0.82 (0.76–0.88), 0.74 (0.66–0.82), 0.49 (0.45–0.55), and 0.81 (0.75–0.87), respectively. Conversely, increased levels of IL6R, IL1R1, ITPKA, IL1RL1, KYNU, LAYN, and LRP11 proteins were linked to an elevated risk of allergic diseases, with corresponding odds ratios of 1.04 (1.03–1.05), 1.25 (1.18–1.34), 1.48 (1.25–1.75), 1.14 (1.11–1.18), 1.09 (1.05–1.12), 1.96 (1.56–2.47), and 1.05 (1.03–1.07), respectively. Bayesian colocalization analysis suggested that LAYN (coloc.abf‐PPH4 = 0.819) and TNFAIP3 (coloc.abf‐PPH4 = 0.930) share the same variant associated with allergic diseases. Conclusions Our study demonstrates a causal association between the expression levels of TNFAIP3 and LAYN and the risk of allergic diseases, suggesting them as potential drug targets for these conditions, warranting further clinical investigation.

A multi-omics Mendelian randomization identifies putatively causal genes and DNA methylation sites for asthma

SNPs Identified by GWAS Affect Asthma Risk Through DNA Methylation and Expression of Cis-Genes in Nasal (airway) Epithelium

Potential drug targets for asthma identified in the plasma and brain through Mendelian randomization analysis

m6A echoes with DNA methylation: Coordinated DNA methylation and gene expression data analysis identified critical m6A genes associated with asthma

Integrative analysis identifies gene signatures mediating the effect of DNA methylation on asthma severity and lung function

Transcriptome-Wide M6a Methylome and M6a-Modified Gene Analysis in Asthma.

Causal effects of genetically determined blood metabolites on asthma: a bidirectional Mendelian randomization study

Unspecified asthma, childhood-onset, and adult-onset asthma have different causal genes: a Mendelian randomization analysis

Unveiling genetic links between gut microbiota and asthma: a Mendelian randomization

Genetic liability to asthma and risk of cardiovascular diseases: A Mendelian randomization study

DNA methylation and gene expression profiles to identify childhood atopic asthma associated genes

Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma

Identification of potential drug targets for allergic diseases from a genetic perspective: A mendelian randomization study

Causal Link between Human Blood Metabolites and Asthma: An Investigation Using Mendelian Randomization

Coordinated DNA Methylation and Gene Expression Data for Identification of the Critical Genes Associated with Childhood Atopic Asthma

Lipid Metabolism-Related Genes Are Involved in the Occurrence of Asthma and Regulate the Immune Microenvironment

Employing a synergistic bioinformatics and machine learning framework to elucidate biomarkers associating asthma with pyrimidine metabolism genes

Assessing causal relationships between gut microbiota and asthma: evidence from two sample Mendelian randomization analysis

Prioritization of candidate causal genes in GWAS signals of asthma in UK Biobank

Prioritization of candidate causal genes for asthma in susceptibility loci derived from UK Biobank

Integrated genomics analysis highlights important SNPs and genes implicated in moderate-to-severe asthma based on GWAS and eQTL datasets